Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2008, Vol. 13 ›› Issue (10): 1158-1162.

Previous Articles     Next Articles

Pharmacokinetics of icotinib in Beagle dog studied by using LC/MS/MS method

GUAN Zhong-min1, CHEN Xiao-yan2, ZHONG Da-fang1,2, WANG Yin-xiang3   

  1. 1Shenyang Pharmaceutical University, Shenyang110016, Liaoning, China;
    2Shanghai Institute of Materia Medi-ca, Chinese Academy of Sciences, Shanghai 201203, China;
    3Zhejiang Beta Pharma Inc ., Hangzhou 310004,Zhejiang, China
  • Received:2008-05-28 Revised:2008-10-16 Online:2008-10-26 Published:2020-10-19

Abstract: AIM: To develop an LC/MS/MS meth-od for the determination of icotinib in dog plasma and study the pharmacokinetics of icotinib.METHODS: Icotinib was administered to 32 Beagle dogsvia intrave-nous bolus (10 mg/kg) or oral dosing (10, 20 or 40 mg/kg) administration after randomly dividing into 4 groups.The concentrations of icotinib in dog plasma were detected by using LC/MS/MS method, and the pharmacokinetic parameters were calculated.RESULTS: The linear calibration curves were obtained in the concentration range of 0.5 -10000 ng/mL .The relative standard deviation (RSD) of intra-day and in-ter-day was less than 10%.The value of area under the curve (AUC0-t ) was (27.3 ±15.3) μgmL-1。h after intravenous bolus administration.The values of AUC0-t were (7.47 ±3.30) , (23.5 ±11.5) and (54.5 ±24.9) μgmL-1。h after oral dosing for the three groups, respectively .The absolute bioavailability of icotinib in dog was 27.4%.CONCLUSION: The method is sensitive, selective and proved to be suitable for preclinical investigation of icotinib pharmacokinet-ics.

Key words: icotinib, pharmacokinetics, LC/MS/MS, Beagle dog

CLC Number: